Gilead Delays Harmful Changes to Patient Assistance Program Until January 1, 2022

Last week, Gilead issued a statement that it is delaying a change to its Advancing Access® Patient Assistance/Medication Assistance Program (PAP/MAP) until January 1, 2022. Gilead previously announced that, effective Oct. 1, 2021, pharmacies dispensing drugs to clients enrolled in the PAP/MAP would only be reimbursed for “the amount paid for each bottle plus a dispensing fee and an administrative…

New Research Shows 340B Hospitals Provide More Medication Access Services Than Non-340B Hospitals

Below is a press release issued by CV340B highlighting new research showing that 340B hospitals provide more medication access services than non-340B hospitals.  The research was performed by the University of Illinois Chicago and funded, in part, by CV340B. *** CV340B PRESS STATEMENT ON MEDICATION ASSISTANCE PROGRAM STUDY (D0942315)CV340B PRESS STATEMENT ON MEDICATION ASSISTANCE PROGRAM…

HHS issues proposal to further delay the Trump Administration’s 340B insulin final rule

On March 9, 2021 the Department of Health and Human Services (HHS) issued a proposal to further delay implementation of the Trump Administration’s final rule that would require federally qualified health centers (FQHCs) to provide insulin and injectable epinephrine to low-income patients at the price the FQHC pays for those drugs under the 340B program. …

Express Scripts Issues 340B Claims Identification Requirements

Express Scripts, a large US-based PBM, announced a new 340B retrospective claims identification requirement.  The new policy may impose significant burdens on 340B pharmacies and threaten the viability of safety net providers. On February 24, Express Scripts, one of the largest pharmacy benefit managers (PBMs) in the United States, issued a notice stating that, beginning March 1, pharmacies…

PRESS STATEMENT: CV340B Names Advisory Council

  March 2, 2021 PRESS STATEMENT:  FOR IMMEDIATE RELEASE                                Contact:  Peggy.Tighe@PowersLaw.com CV340B Names Advisory Council – Prominent 340B Leaders Join National Efforts to Educate, Enable, and Inspire Support for the 340B Drug Pricing Program   Today, Community Voices for 340B (CV340B) announced the appointment of seven leaders who have long served safety net providers participating…

226 Members of Congress Sign Letter Condemning Manufacturer Actions

In a letter, led by Representatives Spanberger, Axne, Matsui, McKinley, sent to Acting HHS Secretary Norris Cochran, 226 Members of Congress called on HHS to take immediate action against manufacturers that refuse to provide discounted drugs to community safety net providers and require manufacturers to reimburse community safety net providers for overcharges. The also called on HHS…